Professor, Medicine, UCSF School of Medicine
Internal Medicine
Dr. Francis Y. Yao, MD
|
|
Give Review
Francis is an expert in the field of Internal Medicine. He attended Albert Einstein College of Medicine of Yeshiva University. He received awards:"CMS Meaningful Use Stage 1 Certification". Doctor Francis Y. Yao, MD has written publications. He has 56 publications published with PubMed. The lastest paper is: 'Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist LifeExpectancy?' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Re-accessing the Boundaries of Liver Transplantation for Hepatocellular Carcinoma: Where Do We Stand with Tumor Down-staging?
- Liver Transplantation for Hepatocellular Carcinoma: Analysis of Factors Predicting Outcome in 1074 Patients in OPTN Region 5.
- The Potential Role of the Donor in Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
- Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma.
- Downstaging of hepatocellular Cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria.
- Evaluating the validity of MELD exception points for HCC patients with multiple nodules <2cm.
- Alpha-fetoprotein level > 1000 ng/mL as an exclusion criteria for liver transplantation in patients with hepatocellular carcinoma meeting the milan criteria.
- Hepatic artery and Biliary complications in liver transplant recipients receiving pre-transplant transarterial chemoembolization.
- Time-to-transplant as a predictor of hepatocellular carcinoma recurrence after liver transplant.
- Alpha-fetoprotein >1000 ng/mL as an Exclusion Criterion for Liver Transplantation in Patients with Hepatocellular Carcinoma Meeting Milan Criteria.
- Combined Effects of Recipient Age and Model for End-Stage Liver Disease Score on Liver Transplantation Outcomes.
- Conundrum of treatment for early-stage hepatocellular carcinoma: Radiofrequency ablation instead of liver transplantation as the first-line treatment?
- Outcome After Liver Transplantation in Patients with Hepatocellular Carcinoma with a Low Risk of Dropout from the Transplant Waiting List.
- Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy.
- Validating post-transplant hepatocellular carcinoma recurrence data in the UNOS database.
- Moving Past "One Size (and Number) Fits All" in the Selection of Candidates with Hepatocellular Carcinoma for Liver Transplant.
- Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
- Factors Associated with Outcomes and Response to Therapy in Patients with Infiltrative Hepatocellular Carcinoma.
- Imaging predictors of the Response to transarterial chemoembolization in patients with hepatocellular carcinoma: A radiological-pathological correlation.
- Do Preoperative Inflammatory Markers Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma?
- Does a patient qualify for liver transplantation after down-staging of hepatocellular carcinoma?
- Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.
- Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.
- Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation.
- Liver transplantation for hepatocellular carcinoma.
- Liver transplantation for hepatocellular carcinoma: the Hepatitis C quandary.
- Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation--yes.
- Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number?
- A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
- Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related Cirrhosis.
- Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
- Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
- Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
- A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications f...
- Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and Cirrhosis.
- Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
- Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.
- Effect of midfacial asymmetry on nasal axis deviation: indications for use of the subalar graft.
- Elevated alpha-fetoprotein levels in hepatocellular carcinoma.
- The role of the interventional radiologist. Transjugular procedures.
- Intramuscular Hepatitis B immune globulin combined with lamivudine for prophylaxis against Hepatitis B recurrence after liver transplantation.
- Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria.
- Lamivudine treatment in patients with severely decompensated Cirrhosis due to replicating hepatitis B infection.
- Lamivudine treatment is beneficial in patients with severely decompensated Cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a c...
- Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
- Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging.
- Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma.
- De novo non-alcoholic fatty liver Disease following orthotopic liver transplantation.
- High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari Syndrome.
- The impact of pre-operative loco-Regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
- Should surveillance for hepatocellular carcinoma be increased in patients with Cirrhosis and small liver nodules?
- De novo malignancies following liver transplantation: a case-control study with long-term follow-up.
- Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation.
- Expanded criteria for liver transplantation in patients with hepatocellular carcinoma.
- Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
Schools
Albert Einstein College of Medicine of Yeshiva University
Stanford University Hospital
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Basic HMO
- Choice Plus POS II
- Vitalidad Plus California Con Aetna
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Enhanced Exclusive for Small Business HMO
- Local Access Plus HMO
- Brown & Toland Physicians
- Cigna HMO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Delta Health System
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- WholeCare Network HMO
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1134177470 | |
| NPPES Provider LastName | YAO | |
| NPPES Provider FirstName | FRANCIS | |
| NPPES Provider ZIPCode | 941430001 | |
| NPPES Provider State | CA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 789.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134177470 |
| Last Name Of The Provider | YAO |
| First Name Of The Provider | FRANCIS |
| View All |
Similar Doctors
|
|
Dr. Lukejohn W. Day, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael W. Sdao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hugo Q. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanjiv N. Singh, MD |
|
|
Dr. James C. Ryan, MD |
|
|
Dr. Jeffrey M. Aron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikhil Agarwal, MD
This Doctor is OpenDoctor Recommended.
|